Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Medicare Part D Coverage & PA | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy N/A

    AmeriHealth Medicare Part D Drug Coverage and Utilization Management Criteria — Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists drugs covered under the AmeriHealth Medicare PPO formulary and details utilization management requirements (prior authorization, step therapy, quantity limits), clinical requirements, prescriber and age restrictions, and coverage durations affecting members and prescribing providers.

    Policy Summary
    PayerAmeriHealth
    PolicyMedicare Part D drug coverage & utilization management (pharmacy & specialty)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewOct 17, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization with documented diagnosis, required prior therapy trials, and specialist involvement as specified for the requested agent.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~100+listed products in this partial extract (document is longer)
    PA, ST, QLutilization management types described
    Prescriber restrictionsspecialist prescribing required
    Indefinitecoverage durations often

    Coverage Criteria (by product / indication)

    Adalimumab (Humira and biosimilars) - Example initial criteria

    Covered when ALL of the following are met for the specified indications

    Adalimumab initial coverage: 1) Diagnosis consistent with the requested indication (e.g., RA, AS, JIA, PsA, PsO, CD, UC, HS, UV) as documented in the medical record. 2) Inadequate response or intolerance to the specified prior therapy(ies) required for the indication (examples: RA—failure/intolerance to ≥1 DMARD such as methotrexate; AS—failure/intolerance to NSAID/COX2 or methotrexate as applicable; JIA—failure/intolerance to methotrexate/other listed agents). 3) No concurrent therapy with any other biologic DMARD (e.g., TNF antagonists) per exclusion. 4) Prescribed by or in consultation with the specialist appropriate to the indication (e.g., rheumatologist for RA/AS/JIA; dermatologist for PsO/HS; gastroenterologist for CD/UC; ophthalmologist for UV).as specified per indication

    Coverage duration: Indefinite where listed.

    AIMOVIG (CGRP inhibitor) - Migraine initial criteria

    Covered when ONE of the following inclusion pathways is met

    Policy Summary
    PayerAmeriHealth
    PolicyMedicare Part D drug coverage & utilization management (pharmacy & specialty)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewOct 17, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization with documented diagnosis, required prior therapy trials, and specialist involvement as specified for the requested agent.
    SourceLink
    On This Page
    Coverage Criteria (by product / indication)Initial Therapy Criteria (top-level initial approvals)Continuation / Reauthorization CriteriaStep Therapy RequirementsProvider Actions, Prior Authorization & DocumentationCoding and Clinical ThresholdsQuantity Limits and Course LimitsSite of Care and Billing ConsiderationsDefinitions and Diagnostic ThresholdsBackground and Scope
    Episodic migraine pathway:
    Diagnosis of episodic migraine (4–14 headache days/month) AND inadequate response or intolerance or contraindication to two specified oral prophylactic medications after appropriate trials (examples: topiramate; divalproex/valproic acid; a beta-blocker such as metoprolol/propranolol/timolol/atenolol/nadolol; a tricyclic antidepressant such as amitriptyline or nortriptyline; an SNRI such as venlafaxine or duloxetine; candesartan).
    episodic 4–14 days/month

    Prescriber: neurologist/headache specialist; Initial coverage 6 months.

    Chronic migraine pathway: Diagnosis of chronic migraine (≥15 headache days/month) AND inadequate response or intolerance or contraindication to two specified oral prophylactic medications after appropriate trials (examples above).≥15 days/month

    Prescriber: neurologist/headache specialist; Initial coverage 6 months.

    Ampyra (dalfampridine) - Multiple sclerosis

    Covered when ALL of the following are met

    Ampyra initial: 1) Diagnosis of multiple sclerosis with documented walking impairment. 2) Confirmation that member has difficulty walking and (if applicable) inadequate response or intolerance to branded dalfampridine where specified. 3) No history of seizure and creatinine clearance >50 mL/min. 4) Prescribed by or in consultation with a neurologist.CrCL > 50 mL/min

    Coverage: remainder of contract year for initial and reauth; reauth requires documented improvement in walking speed.

    ARIKAYCE (amikacin liposome inhalation) - MAC lung disease

    Covered when ALL of the following are met

    Arikayce initial: 1) Diagnosis of Mycobacterium avium complex (MAC) lung disease. 2) Drug is being used as part of a combination antibacterial regimen. 3) Patient has not achieved at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen. 4) Prescribed by or in consultation with a pulmonologist or infectious disease specialist.failed ≥6 months multidrug regimen without two negative sputum cultures

    Coverage: remainder of contract year.

    Austedo indications and requirements

    Coverage when criteria for specific sleep disorders are met

    Austedo indications: For narcolepsy: diagnosis confirmed by sleep study unless prescriber documents why a sleep study is not feasible. For OSAHS: sleep study confirmation with ≥5 obstructive respiratory events/hour plus one listed symptom. For shift work sleep disorder (SWSD): symptoms ≥3 months associated with work period or sleep study demonstrating disturbed circadian pattern. Prescribed by or in consultation with a neurologist or sleep specialist.sleep study confirmation; >=5 obstructive events/hour

    Coverage duration: indefinite.

    Tardive Dyskinesia and Chorea (Huntington's)

    Coverage when TD or chorea‑Huntington's criteria are met

    Tardive Dyskinesia (TD) initial: Diagnosis of tardive dyskinesia AND documentation of baseline AIMS AND either (a) persistent symptoms despite a trial of dose reduction/taper/discontinuation of the offending medication, or (b) member is not a candidate for such a trial. Prescribed by or in consultation with a neurologist or psychiatrist.baseline AIMS documented

    Initial coverage 3 months; reauth requires documented clinical response (improvement in AIMS).

    Chorea – Huntington's disease: Diagnosis of chorea associated with Huntington's disease; prescribed by or in consultation with a neurologist or psychiatrist.

    Coverage indefinite.

    Auvelity — MDD criteria

    Major Depressive Disorder — prior treatment requirement

    Auvelity (MDD): Diagnosis of major depressive disorder AND inadequate response or inability to tolerate two formulary antidepressants indicated for MDD (examples: bupropion, venlafaxine XR, sertraline).trial of two antidepressants

    Prescriber documents prior trials; coverage indefinite.

    Cayston criteria

    Cystic Fibrosis specific criteria

    Cayston (CF): 1) Diagnosis of cystic fibrosis. 2) Evidence of Pseudomonas aeruginosa in the lungs with susceptibility demonstrating sensitivity to aztreonam. 3) FEV1 between 25% and 75% of predicted. 4) Prescribed by or in consultation with a pulmonologist, infectious disease specialist, or CF center specialist.FEV1 25%-75%

    Coverage: remainder of contract year; reauth requires evidence of persistent Pseudomonas and positive clinical response (e.g., improved FEV1).

    Cholbam criteria

    Bile acid synthesis and peroxisomal disorder criteria

    Cholbam (BASD/PD): BASD initial: diagnosis of bile acid synthesis disorder due to a single enzyme defect. PD initial: diagnosis of peroxisomal disorder used adjunctively when manifestations include liver disease, steatorrhea, or fat‑soluble vitamin malabsorption. Prescribed by hepatologist/gastroenterologist/geneticist. Initial coverage 3 months; reauth indefinite with documentation of improved liver function tests.

    Tadalafil (BPH) criteria

    Tadalafil for BPH requires prior therapy

    Tadalafil (BPH): 1) Diagnosis of benign prostatic hyperplasia. 2) Inadequate response or inability to tolerate an alpha blocker (e.g., tamsulosin) or a 5‑alpha reductase inhibitor (e.g., dutasteride, finasteride). 3) No concurrent use of nitrates.

    Coverage: indefinite.

    Cimzia criteria

    Cimzia (certolizumab) criteria across multiple indications

    Cimzia (multiple indications): Diagnosis-specific requirements per indication with documentation of inadequate response or intolerance to required prior therapies (commonly failure/intolerance to one or two listed agents such as adalimumab, etanercept, secukinumab, tofacitinib/upadacitinib, ustekinumab, etc.). No concurrent biological DMARD or TNF antagonist. Prescribed by appropriate specialist; age limits per indication apply.prior trials of listed agents

    Coverage indefinite where listed.

    Cinryze criteria

    Hereditary angioedema prophylaxis criteria

    Cinryze (HAE prophylaxis): Diagnosis of hereditary angioedema and use for prophylaxis of HAE attacks; prescribed by or in consultation with allergist/immunologist or pulmonologist; member aged ≥6 years. Subject to Part B vs Part D review.

    Coverage indefinite.

    Cosentyx criteria

    Cosentyx criteria for psoriasis, psoriatic arthritis, ankylosing spondylitis and others

    Cosentyx (PsO, PsA, AS, nr-axSpA, ERA, HS): Diagnosis per indication and inadequate response or inability to tolerate the required prior therapies (e.g., NSAIDs/methotrexate, or failure of listed biologics) as specified for each disease. No concurrent biologic DMARDs or TNF antagonists. Prescriber specialty and age limits vary by indication.prior trials as specified

    Coverage indefinite.

    Dalfampridine criteria

    Dalfampridine criteria for multiple sclerosis

    Dalfampridine (MS): 1) Diagnosis of multiple sclerosis with difficulty walking documented. 2) No history of seizure and baseline creatinine clearance >50 mL/min. 3) Prescribed by or in consultation with a neurologist. 4) Reauthorization requires documented improvement in walking speed.CrCL > 50 mL/min

    Coverage: remainder of contract year for initial and reauth.

    Deferasirox criteria

    Deferasirox NTDT and transfusional iron overload criteria

    Deferasirox indications: NTDT initial: diagnosis of chronic iron overload in non‑transfusion dependent thalassemia with liver iron concentration (LIC) ≥5 mg Fe/g dw and serum ferritin >300 µg/L (≥2 values within prior 2 months); age ≥10 years. CIO‑BT initial: chronic iron overload due to transfusions with serum ferritin consistently >1000 µg/L (≥2 values in prior 2 months); age ≥2 years. Initial coverage 3 months; continuation 6 months requires evidence of decreased ferritin or LIC.LIC >=5 mg Fe/g dw; ferritin thresholds specified

    Prescriber documents required labs.

    Diacomit criteria

    Diacomit (stiripentol) criteria for Dravet syndrome

    Diacomit (Dravet): Diagnosis of seizures associated with Dravet syndrome and use in combination with clobazam; prescribed by or in consultation with a neurologist. Member ≥6 months of age. Coverage indefinite; continuation approved for ongoing therapy.

    Doptelet criteria

    Doptelet criteria for chronic liver disease and chronic immune thrombocytopenia

    Doptelet (CLD, ITP): CLD: diagnosis of chronic liver disease with baseline platelet count <50,000/mcL and member scheduled for a procedure (coverage 1 month). ITP: diagnosis of chronic/relapsed/refractory ITP with baseline platelet count <30,000/mcL and inadequate response or intolerance to one of corticosteroids, IVIG, splenectomy, or rituximab; prescribed by hematologist/oncologist. Continuation requires positive clinical response (increased platelet count). Part B prerequisite may apply.platelet thresholds as specified

    ITP coverage 12 months initial; CLD coverage 1 month.

    Dupixent criteria

    Dupixent (dupilumab) diagnosis-specific criteria

    Dupixent (AD, Asthma, CRSwNP, EoE, BP): Atopic dermatitis: moderate‑to‑severe AD with inadequate response or intolerance to at least one topical therapy (medium+ potency steroid, tacrolimus, pimecrolimus, or crisaborole). Asthma: oral corticosteroid dependence OR eosinophil criteria (≥150 cells/µL baseline or ≥300 within past 12 months) plus prior exacerbation/intubation/hospitalization and use with medium‑high dose ICS plus another controller. CRSwNP: diagnosis and concurrent intranasal corticosteroid after inadequate response. EoE: symptoms of esophageal dysfunction, ≥15 eosinophils/HPF, other causes excluded, weight ≥15 kg, inadequate response to ≥8‑week PPI or topical esophageal steroid. Bullous pemphigoid: biopsy‑confirmed BP and used with tapering oral corticosteroids. Exclusion: concurrent biologic therapy. Prescriber and age restrictions vary by indication. Continuation/reauthorization requires documented positive clinical response per indication.eosinophil counts and histology thresholds as specified

    Coverage durations vary by indication; many indefinite where listed.

    Atopic Dermatitis (AD) - Initial

    Covered when ALL of the following are met

    AD initial criteria: (1) Diagnosis of moderate‑to‑severe atopic dermatitis; (2) inadequate response or intolerance to ONE of: medium‑potency or higher topical steroid, topical tacrolimus, topical pimecrolimus, or topical crisaborole (eucrisa).

    Prescriber: dermatologist/allergist/immunologist; coverage indefinite.

    Asthma - Initial

    Covered when ALL of the following are met

    Asthma initial: (1) One of: oral corticosteroid‑dependent asthma OR blood eosinophils ≥150 cells/µL at baseline or ≥300 cells/µL within past 12 months; (2) One of: ≥1 exacerbation requiring systemic corticosteroids in prior 12 months OR prior intubation OR asthma‑related hospitalization in prior 12 months; (3) Medication will be used in addition to BOTH medium‑to‑high dose inhaled corticosteroid (≥500 µg fluticasone eq/day) AND one additional controller medication. Prescribed by allergist/immunologist or pulmonologist. Reauth requires documented positive clinical response.eosinophil thresholds as specified

    Coverage initial 12 months (where listed).

    CRSwNP - Initial

    Covered when ALL of the following are met

    CRSwNP initial: (1) Diagnosis of chronic rhinosinusitis with nasal polyposis; (2) concurrent use of intranasal corticosteroid; (3) inadequate response to intranasal steroid as applicable. Prescribed by ENT/allergist/immunologist/pulmonologist. Reauth requires positive clinical response (e.g., reduced NPS).

    Coverage durations per product (commonly 12 months).

    Eosinophilic Esophagitis (EoE) - Initial

    Covered when ALL of the following are met

    EoE initial: (1) Diagnosis of eosinophilic esophagitis with symptoms of esophageal dysfunction; (2) histology showing ≥15 intraepithelial eosinophils per HPF; (3) other causes excluded; (4) member weight ≥15 kg; (5) inadequate response or intolerance to an ≥8‑week trial of PPI or topical esophageal corticosteroid. Prescribed by gastroenterologist/allergist. Reauth requires demonstrated clinical/histologic improvement.>=15 eosinophils/HPF

    Prurigo Nodularis (PN) - Initial

    Covered when ALL of the following are met

    PN initial: (1) Diagnosis of prurigo nodularis. (2) Prescribed by or in consultation with dermatologist/allergist/immunologist. Reauth requires documentation of positive clinical response such as reduction in number of nodular lesions or symptom improvement.

    Coverage duration commonly 12 months.

    COPD - Initial

    Covered when ALL of the following are met

    COPD initial: (1) Diagnosis of COPD. (2) Evidence of Type 2 inflammation (blood eosinophils ≥300 cells/µL at baseline). (3) Member is receiving triple therapy (ICS+LAMA+LABA) for ≥3 months OR if ICS contraindicated, LAMA+LABA. (4) One of: ≥2 exacerbations requiring systemic corticosteroids in past 12 months OR COPD‑related hospitalization. (5) Member experiences dyspnea during everyday activities. Prescriber: pulmonologist/allergist. Reauth requires documented positive clinical response.blood eosinophils >=300 cells/mcL

    Coverage duration typically 12 months.

    Migraine (EMGALITY) - Initial (episodic or chronic)

    Covered when ONE of the following inclusion criteria are met

    Migraine initial: (A) Episodic migraine (4–14 days/month) AND inadequate response/intolerance/contraindication to TWO prophylactic agents (topiramate; divalproex/valproic acid; beta‑blocker; tricyclic; SNRI) after appropriate trials; OR (B) Chronic migraine (≥15 days/month) AND inadequate response/intolerance/contraindication to TWO prophylactic agents (including candesartan as applicable). Prescriber: neurologist/headache specialist. Initial coverage typically 6 months with reauth criteria requiring clinical benefit.episodic 4-14 or >=15 days/month

    Avoid concomitant use with another injectable CGRP inhibitor (exclusion).

    FASENRA - Severe Asthma (Initial)

    Covered when ALL of the following are met

    Fasenra severe asthma initial: (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by blood eosinophils ≥150 cells/µL at initiation if oral corticosteroid‑dependent or ≥300 cells/µL otherwise. (2) One of: ≥1 exacerbation requiring systemic corticosteroids in past 12 months OR prior intubation OR asthma‑related hospitalization in prior 12 months. (3) Member is treated with high‑dose ICS plus additional controller or maximally dosed ICS/LABA. Prescriber: pulmonologist/allergy‑immunology. Subject to Part B vs Part D review.blood eosinophil thresholds as specified

    Initial and reauth durations commonly 12 months.

    Rheumatologic Indications (ENBREL) - Initial

    Covered when ALL of the following are met

    ENBREL rheumatology initial: (1) Diagnosis corresponding to the rheumatologic indication (e.g., moderate‑severe RA, PsA, PJIA, PsO, AS). (2) Inadequate response or intolerance to the required conventional therapy for the indication (e.g., RA—failure/intolerance to ≥1 DMARD). (3) No concurrent biologic DMARD therapy. Prescribed by or in consultation with a rheumatologist or other indicated specialist.prior trials as specified

    Coverage indefinite.

    EPIDIOLEX - Dravet, LGS, TSC

    Covered when ALL of the following are met

    Epidiolex initial (DS, LGS, TSC): Dravet syndrome: inadequate response or intolerance to clobazam, valproic acid, or topiramate; baseline CBC, serum transaminases, and total bilirubin prior to initiation; concurrent use with other anti‑epileptics as appropriate. LGS: inadequate response/intolerance to listed agents and baseline labs. TSC: concurrent use with anti‑epileptics and baseline labs. Prescribed by neurologist. Age limits per indication (≥1 year).

    Coverage indefinite; continuation requires documented benefit.

    High-Dose Opioid Therapy - New to High Dose

    Covered when ONE of the following is met

    New to high dose opioid therapy: (A) Pain associated with cancer; OR (B) chronic non‑cancer pain AND BOTH: (1) member is opioid tolerant (example: at least one week where total daily dose >=30 mg oxycodone or 60 mg oral morphine or 8 mg oral hydromorphone or equianalgesic dose), AND (2) member has been evaluated for non‑opioid prescription pharmacologic treatment prior to initiation of high‑dose opioid therapy.>= specified MED equivalents

    Initial high‑dose requests require opioid tolerance or cancer pain documentation; coverage remainder of contract year.

    High Dose Opioid Therapy

    Requirements for New to High Dose Opioid Therapy and Continuing High Dose Opioid Therapy

    New to high dose opioid therapy: ONE of the following: (A) pain associated with cancer, OR (B) chronic non‑cancer pain AND BOTH: (1) member is opioid tolerant (e.g., examples of daily dose thresholds) AND (2) member has been evaluated for non‑opioid prescription pharmacologic treatment prior to initiation.>= specified MED equivalents

    Applies to listed high‑dose opioid products.

    Continuing high dose opioid therapy: ONE of the following: (1) pain associated with cancer OR (2) chronic non‑cancer pain AND ALL: (a) pain assessed within last 6 months, (b) clinically meaningful improvement in pain and functioning outweighs risks, (c) not being treated for substance abuse.morphine equiv >=90 mg/day for continuing criteria

    Continuation requires documentation as above.

    Growth Disorders

    Criteria for growth-related products (cartridge 5 mg/1.5 mL, Increlex, etc.)

    Growth therapy continuation: Annual clinical re‑evaluation by the treating endocrinologist AND documentation of increased growth velocity from baseline where specified; for some diagnoses require no history of renal transplant or closed epiphyses and expected adult height not yet obtained.12 months coverage durations commonly applied

    Prescriber: endocrinologist; continuation typically 12 months.

    Severe primary IGF‑1 deficiency initial: Diagnosis of severe primary IGF‑1 deficiency AND height SDS ≤ ‑3.0 AND basal IGF‑1 SDS ≤ ‑3.0 AND normal or elevated growth hormone; prescribed by endocrinologist.SDS <= -3.0

    Applies to Increlex initial approval; coverage 12 months.

    Valbenazine (Ingrezza)

    Requirements for valbenazine (Ingrezza)

    Tardive Dyskinesia (Initial): Diagnosis of moderate to severe tardive dyskinesia AND documentation of baseline AIMS AND either persistent symptoms despite trial of dose reduction/taper/discontinuation of offending medication OR member is not a candidate for such trial. Prescribed by or in consultation with neurologist/psychiatrist.baseline AIMS documented

    Initial approval 3 months; reauthorization requires documented clinical response (improved AIMS).

    Chorea - Huntington Disease: Diagnosis of chorea associated with Huntington's disease; prescribed by or in consultation with neurologist or psychiatrist.

    Coverage indefinite.

    Ivacaftor (Kalydeco)

    CFTR mutation–based coverage criteria for ivacaftor

    Cystic Fibrosis (Kalydeco): Diagnosis of cystic fibrosis with documentation of a CFTR mutation responsive to ivacaftor based on clinical or in‑vitro data AND mutation confirmed by an FDA‑cleared CF mutation test with bidirectional sequencing when recommended. Prescribed by or in consultation with pulmonologist or CF center specialist.age limits per formulation (granules/tablets)

    Coverage indefinite where listed.

    TOBI Podhaler

    Criteria for TOBI Podhaler in cystic fibrosis

    Cystic Fibrosis (TOBI Podhaler): Diagnosis of cystic fibrosis AND evidence of Pseudomonas aeruginosa in the lungs AND FEV1 between 25% and 80% of predicted AND member not colonized with Burkholderia cepacia. Prescribed by/consultation with pulmonologist/ID/CF center specialist. Member ≥6 years.FEV1 25%-80%

    Coverage: remainder of contract year.

    Livtencity (CMV)

    Criteria for Livtencity for CMV

    Cytomegalovirus (Livtencity): Diagnosis of CMV infection/disease AND recipient of hematopoietic stem cell transplant or solid organ transplant AND inadequate response or intolerance to at least a 2‑week trial of IV ganciclovir, oral valganciclovir, IV foscarnet, or IV cidofovir AND member weighs ≥35 kg. Prescribed by transplant/infectious disease/oncology specialist.age >=12 years; weight >=35 kg

    Coverage duration 8 weeks.

    Immune Globulin (Gamunex-C)

    Indications and continuation criteria for immune globulin (Gamunex-C)

    IG – Part D medically necessary indications: One of the listed indications is present (examples include autoimmune mucocutaneous blistering diseases with inadequate response to conventional therapy; acute ITP for bleeding management or to raise platelets pre‑procedure; chronic ITP meeting duration and platelet thresholds; chronic B‑cell CLL with IgG <600 mg/dL and recurrent infections; HSCT with IgG <400 mg/dL; Guillain‑Barre with impaired function). Initial coverage commonly 6 months; continuation requires documentation of clinical improvement appropriate to the diagnosis.platelet/IgG thresholds as specified

    Prescriber with expertise in IG management recommended; subject to Part B vs Part D review where noted.

    Kerendia (finerenone)

    Kerendia coverage criteria

    Kerendia (finerenone): Diagnosis of chronic kidney disease associated with type 2 diabetes AND either a minimum 30‑day trial of a maximally tolerated ACE inhibitor or ARB with intent to continue therapy OR contraindication/intolerance to ACE/ARB. Prescribed by appropriate specialist.30-day ACEi/ARB trial

    Coverage indefinite.

    Rheumatology Biologics Step Therapy

    Prior therapy requirements for certain biologics in rheumatologic conditions

    Rheumatology biologics step therapy: Diagnosis of the specified rheumatologic condition AND inadequate response or intolerance to the required prior therapies (commonly trials of conventional DMARDs such as methotrexate and failure of or intolerance to one or more biologics as specified). Documentation that trials are inappropriate may be accepted in select circumstances. Prescribed by or in consultation with a rheumatologist.typically failure of one or two prior agents as specified

    Concurrent biologic therapy is excluded.

    Lidocaine 5% patch (PHN, DPN)

    Covered when ALL of the following are met

    Lidocaine patch criteria: Diagnosis of post‑herpetic neuralgia (PHN) or diabetic peripheral neuropathy (DPN) as documented in the medical record; prescriber documents indication; product used per labeling.

    Coverage duration: indefinite; prior authorization required.

    Livtencity (CMV)

    Covered when ALL of the following are met

    Livtencity initial: Diagnosis of CMV infection/disease in transplant recipient AND inadequate response or intolerance to at least 2 weeks of standard antivirals (IV ganciclovir, oral valganciclovir, IV foscarnet, IV cidofovir) AND member weight ≥35 kg AND age ≥12 years. Prescribed by transplant/ID/oncology specialist.weight >=35 kg; age >=12 years

    Coverage duration 8 weeks.

    Modafinil (Narcolepsy, OSAHS, SWSD, MS fatigue)

    Covered when ALL specified diagnostic criteria are met

    Narcolepsy: Diagnosis of narcolepsy confirmed by sleep study unless prescriber documents infeasibility; prescribed by or in consultation with neurologist or sleep specialist.

    Coverage indefinite.

    OSAHS: Diagnosis of obstructive sleep apnea/hypopnea syndrome confirmed by sleep study with ≥5 obstructive respiratory events/hour plus an associated symptom (unless sleep study infeasible); prescribed by or in consultation with neurologist or sleep specialist.>=5 events/hour

    Coverage indefinite.

    Nexletol / Nexlizet (HeFH / Primary hyperlipidemia / CVD high risk)

    Covered when ALL of the following are met

    Nexletol/Nexlizet initial: Diagnosis of HeFH or primary hyperlipidemia or established CVD/high risk AND at least an 8‑week trial of a moderate‑intensity statin at maximally tolerated dose (or documented statin intolerance). AND at least 12 weeks of generic ezetimibe adjunctive therapy to maximally tolerated statin unless contraindicated (requirements differ by product). AND LDL‑C values within last 120 days meeting specified thresholds (e.g., ≥55 mg/dL with ASCVD or ≥100 mg/dL without ASCVD per indication).>=8 weeks statin; >=12 weeks ezetimibe; LDL thresholds specified

    Initial coverage 6 months; continuation 12 months with positive clinical response.

    Posaconazole (invasive aspergillosis / prophylaxis)

    Covered when ALL of the following are met

    Posaconazole (TAI/prophylaxis): Treatment of invasive aspergillosis: documented diagnosis. Prophylaxis in severely immunocompromised patients: inadequate response or intolerance to voriconazole required. Prescribed by or in consultation with infectious disease/transplant/hematology‑oncology specialist. Age and dosing criteria per indication.age thresholds per indication

    Coverage duration: remainder of contract year for many uses; subject to additional review where applicable.

    Nucala (mepolizumab) indications and criteria

    Part D medically necessary when ONE of the following indication-specific criteria sets are met

    Nucala — Severe asthma (eosinophilic): Diagnosis of severe asthma with eosinophilic phenotype (blood eosinophils ≥150 cells/µL at initiation if oral steroid‑dependent OR ≥300 cells/µL within past 12 months) AND ≥1 exacerbation requiring systemic corticosteroids in past 12 months or prior intubation or hospitalization AND current treatment with high‑dose ICS plus an additional controller (or maximally dosed ICS/LABA). Prescriber: pulmonologist or allergy/immunology. Age ≥6 years. Initial and reauth durations commonly 12 months.eosinophil thresholds as specified

    Exclusion: concurrent biologic therapy.

    Nucala — HES: Diagnosis of hypereosinophilic syndrome (HES) ≥6 months, FIP1L1‑PDGFRA negative, pretreatment eosinophils ≥1000 cells/µL, and inadequate response or intolerance to corticosteroids or cytotoxic/immunosuppressive therapy. Prescriber: allergist/immunologist or hematologist. Age ≥12 years.>=1000 cells/µL

    Initial/reauth 12 months.

    Nucala — EGPA/CRSwNP/COPD: Indication‑specific requirements: EGPA—relapsed/refractory to standard care and on corticosteroids; CRSwNP—inadequate response to intranasal corticosteroid for ≥2 months and used with intranasal steroid; COPD—type 2 inflammation and on triple therapy/LAMA+LABA with exacerbation history. Reauth requires positive clinical response measures.

    Prescriber and age restrictions vary by indication.

    Nurtec (rimegepant)

    Covered when ALL of the following are met

    Nurtec — Acute treatment: Diagnosis of migraine with or without aura in adults with <15 headache days/month AND inadequate response or intolerance to one generic triptan. Prescribed by neurologist/headache specialist; initial coverage 6 months; reauth 12 months; cannot be used in combination with another oral CGRP inhibitor.<15 days/month
    Nurtec — Preventive treatment: Episodic migraine (4–18 migraine days/month) AND inadequate response or intolerance to two 4‑week trials of listed prophylactic medications. Prescriber: neurologist/headache specialist. Initial 6 months; reauth 12 months with demonstrated benefit.4-18 days/month

    Avoid combination with other CGRP inhibitors.

    Ofev (nintedanib) — fibrosing ILD/IPF/SSc-ILD

    Covered when ALL of the following are met

    Ofev — IPF/ILD indications: Indication‑specific criteria: IPF—diagnosis confirmed by HRCT or biopsy; chronic fibrosing ILD with progressive phenotype—HRCT showing ≥10% lung volume with fibrotic features and progressive phenotype evidenced by FVC decline, worsening symptoms, or increased fibrosis on imaging. Prescribed by pulmonologist or lung transplant specialist. Initial and reauth durations commonly 12 months; reauth requires stabilization from baseline and liver enzyme monitoring per labeling.>=10% lung volume for fibrotic features

    Olumiant (baricitinib) — RA and Alopecia Areata

    Covered when ALL specified criteria are met

    Olumiant — RA initial: Diagnosis of rheumatoid arthritis with inadequate response or intolerance to two specified agents (examples include adalimumab, Enbrel, Rinvoq, Xeljanz, Orencia) or documentation that trials are inappropriate; prescribed by rheumatologist; no concurrent biologic DMARD or JAK inhibitor.

    Coverage indefinite.

    Olumiant — Alopecia Areata initial: Diagnosis of alopecia areata with ≥50% scalp hair loss, other causes ruled out, and inadequate response or intolerance to at least one prior AA treatment; prescribed by dermatologist.>=50% scalp hair loss

    Coverage indefinite.

    Tavaborole (onychomycosis)

    Covered when ALL of the following are met

    Onychomycosis initial: (1) Diagnosis of toenail onychomycosis due to Trichophyton rubrum or T. mentagrophytes confirmed by KOH prep, culture, or histology; (2) Condition causes debility or ADL disruption; (3) Inadequate response or intolerance to BOTH oral generic terbinafine AND either oral generic itraconazole OR topical generic ciclopirox. Prescriber documents required confirmation and functional impact.

    Coverage duration: 1 year.

    Opiprazole (OPIPZA) — multiple psychiatric indications

    Covered when ALL of the following are met

    Opiprazole (multiple psychiatric indications): Indication‑specific requirements: schizophrenia—diagnosis and inadequate response/intolerance to aripiprazole plus an additional generic formulary antipsychotic; MDD adjunctive—diagnosis and inadequate response/intolerance to aripiprazole and quetiapine; autistic irritability—diagnosis and inadequate response/intolerance to aripiprazole and risperidone; Tourette's—diagnosis and inadequate response/intolerance to aripiprazole. Prescriber documents prior trials; continuation allowed for ongoing therapy.

    Coverage indefinite for continuation.

    Nuplazid (pimavanserin) — Parkinson Disease Psychosis

    Covered when specified criteria are met

    Nuplazid (PD psychosis): Diagnosis of Parkinson disease psychosis with inadequate response or inability to tolerate quetiapine or clozapine documented; prescribed per product guidance.

    Coverage indefinite; continuation allowed.

    Onychomycosis (OPIPZA) — Initial

    Approve when ALL of the following are met:

    Onychomycosis (OPIPZA) — Initial: (1) Diagnosis of toenail onychomycosis due to Trichophyton rubrum or T. mentagrophytes; (2) Confirmation by KOH, culture, or histology; (3) Condition causes debility or ADL disruption; (4) Inadequate response or inability to tolerate BOTH oral terbinafine AND (oral itraconazole OR topical ciclopirox).

    Initial coverage 1 year.

    Aripiprazole product indications

    Approve when ALL of the following are met for each indication:

    Aripiprazole — Schizophrenia: (1) Diagnosis of schizophrenia; (2) Inadequate response or inability to tolerate aripiprazole and an additional generic formulary antipsychotic per policy requirements.

    Coverage indefinite; continuation permitted.

    Aripiprazole — MDD adjunctive: (1) Diagnosis of major depressive disorder for adjunctive treatment; (2) Inadequate response or inability to tolerate aripiprazole and quetiapine as prior trials.

    Coverage indefinite.

    Aripiprazole — Autistic irritability: (1) Diagnosis of irritability associated with autism; (2) Inadequate response or inability to tolerate aripiprazole and risperidone.

    Coverage indefinite.

    Aripiprazole — Tourette's disorder: (1) Diagnosis of Tourette's disorder; (2) Inadequate response or inability to tolerate aripiprazole.

    Coverage indefinite.

    Pulmonary Arterial Hypertension agents — Initial and Continuation

    PAH therapy is covered when ALL initial criteria are met; continuation requires specialist assessment of stabilization or improvement.

    PAH Initial: (1) Documentation of PAH WHO Group I with NYHA Functional Class II–IV; (2) Diagnosis confirmed by right‑heart catheterization or echocardiography; (3) Mean pulmonary artery pressure ≥25 mm Hg at rest (or >30 mm Hg with exertion); (4) Prescribed by or in consultation with a cardiologist or pulmonologist.mean PAP >=25 mm Hg

    Initial coverage typically 6 months; continuation 12 months.

    PAH Continuation: (1) Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist (e.g., clinical status, hemodynamics, exercise capacity).

    Continuation coverage duration: 12 months.

    Praluent (alirocumab) — Hyperlipidemia / ASCVD / HoFH

    Approve when specified LDL‑C thresholds and prior statin trial or documented statin intolerance criteria are met.

    Praluent — HLA initial: (1) Diagnosis of hyperlipidemia AND ONE of: (A) LDL‑C ≥70 mg/dL after minimum 8‑week trial of at least moderate‑intensity statin therapy at maximally tolerated dose, OR (B) documented inability to tolerate statin therapy per defined criteria (rhabdomyolysis with CK >10x ULN, myalgia/myositis with two statins, hepatotoxicity AST/ALT >3x ULN).LDL‑C >=70 mg/dL

    Initial 6 months; continuation 12 months; HoFH criteria separate.

    Praluent — ASCVD: (1) Diagnosis of ASCVD AND ONE of: LDL‑C ≥70 mg/dL after minimum 8‑week trial of at least moderate‑intensity statin OR documented statin intolerance per specified criteria.LDL‑C >=70 mg/dL

    Initial 6 months; continuation 12 months.

    Praluent — HoFH: (1) Diagnosis of homozygous familial hypercholesterolemia AND untreated LDL‑C >500 mg/dL or treated LDL‑C >300 mg/dL AND member receiving other lipid‑lowering therapy AND not used with lomitapide.LDL‑C thresholds as specified

    Continuation requires positive clinical response.

    Osteoporosis / Bone / Osteopenia / Glucocorticoid induced osteoporosis — Part D criteria

    Part D coverage when ALL listed criteria for each condition are met.

    Osteoporosis initial: (1) Diagnosis of osteoporosis confirmed by BMD T‑score ≤ ‑2.5 or history of osteoporotic fracture or multiple risk factors; (2) Inadequate response or intolerance to at least one other osteoporosis medicine OR severely deteriorated condition precluding oral bisphosphonates OR documented moderate to severe renal insufficiency (GFR ≤30‑35 mL/min).BMD T-score <= -2.5

    Coverage duration: 12 months.

    Osteopenia initial: (1) T‑score between ‑1.0 and ‑2.5 AND (2) member is receiving adjuvant aromatase inhibitor therapy for breast cancer OR androgen deprivation therapy for non‑metastatic prostate cancer.T-score between -1.0 and -2.5

    Coverage duration: 12 months.

    Glucocorticoid‑induced osteoporosis initial: (1) Daily prednisone ≥5 mg for ≥3 months; (2) Inadequate response or intolerance to bisphosphonates/hormone therapy/SERMs OR severely deteriorated condition OR documented moderate to severe renal insufficiency (GFR ≤30‑35 mL/min).prednisone >=5 mg/day for >=3 months

    Reauth requires positive clinical response.

    Eltrombopag (Promacta) — Hematology indications

    Approve when ALL initial criteria per indication are met; continuation requires response per indication.

    Eltrombopag — Chronic ITP initial: (1) Diagnosis of relapsed/refractory, persistent, or chronic ITP; (2) Baseline platelet count <30,000/mcL; (3) Clinical risk of bleeding related to thrombocytopenia; (4) Inadequate response or intolerance to one of corticosteroids, IVIG, or splenectomy. Prescribed by hematologist/oncologist. Continuation requires positive clinical response (increase in platelets to avoid clinically important bleeding).platelets <30,000/mcL

    Initial/continuation durations typically 12 months for ITP.

    Eltrombopag — Other hematology indications: Indication‑specific criteria (e.g., first‑line severe aplastic anemia, chronic hepatitis C‑associated thrombocytopenia) per policy with required cytopenia thresholds and specialist prescribing. Continuation per indication requires response criteria.various cytopenia cutoffs

    Coverage durations vary by indication.

    Diabetes therapies (GLP-1 agonists) — general

    Coverage applies with documentation of type 2 diabetes mellitus per diagnostic criteria.

    GLP‑1 diabetes therapy documentation: Submission of medical records confirming diagnosis of type 2 diabetes mellitus defined by laboratory evidence (A1C ≥6.5% OR fasting plasma glucose ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL). For listed GLP‑1 agents, prior inadequate response or intolerance to a minimum 90‑day supply of two preferred GLP‑1 brands may be required per product step therapy rules.A1C >=6.5% or FPG >=126 mg/dL or 2‑hr OGTT >=200 mg/dL

    Coverage duration: indefinite where indicated.

    Hepatitis C DAAs (Epclusa, Harvoni, Mavyret)

    Approve when ALL of the following are met:

    HCV DAA initial: (1) Documentation of the member's hepatitis C genotype. (2) Prescribed regimen consistent with current AASLD/IDSA guidance for the genotype and clinical scenario. Prescriber documents required testing and regimen selection.regimen consistent with AASLD/IDSA guidance

    Coverage duration applied consistent with guidance.

    Yesintek (and similar biologics) — autoimmune/IBD/dermatology

    Part D medically necessary when initial criteria per indication are met and no concurrent biologic DMARDs.

    Yesintek and similar biologics — dermatology/GI initial: Diagnosis of the specified autoimmune/IBD/dermatologic condition (e.g., moderate to severe plaque psoriasis, moderate to severe CD/UC) AND absence of concurrent biologic DMARD therapy AND prescriber specialty consistent with indication (dermatologist for PsO, gastroenterologist for CD/UC). Reauth requires positive clinical response.

    Coverage durations commonly 12 months; concurrent biologic therapy excluded.

    Quinine sulfate — Malaria and Babesiosis

    Approve when ALL initial criteria are met:

    Quinine sulfate — Uncomplicated malaria: Diagnosis of uncomplicated malaria due to Plasmodium falciparum or P. vivax AND either treatment in areas of chloroquine‑sensitive malaria with inadequate response/intolerance to chloroquine/hydroxychloroquine OR treatment in areas of chloroquine‑resistant malaria.

    Coverage duration: 14 days for uncomplicated malaria.

    Quinine sulfate — Babesiosis: Diagnosis of babesiosis as documented in the medical record.

    Coverage duration: 10 days for babesiosis.

    Promacta continuation

    Promacta (eltrombopag) continuation covered when ONE of the following is met:

    Promacta continuation options: (A) For members who started Promacta prior to initiation of interferon: member is currently on antiviral interferon therapy AND reached a platelet threshold that allows initiation of interferon with Promacta; OR (B) For members who started Promacta while on concomitant interferon: member is currently on antiviral interferon therapy. For ITP and other indications, continuation requires positive clinical response (increase in platelet count sufficient to avoid clinically important bleeding).

    Continuation durations vary by indication (commonly 12 months).

    Hyperlipidemia/ASCVD initial criteria

    PCSK9/Repatha coverage (HLA, ASCVD initial) covered when ONE of the following is met:

    PCSK9 — LDL or statin intolerance: (A) LDL‑C ≥70 mg/dL after ≥8‑week trial of at least moderate‑intensity statin therapy at maximally tolerated dose, OR (B) documented inability to tolerate statin therapy per defined criteria (rhabdomyolysis with CK >10x ULN, myalgia/myositis on two statins, hepatotoxicity AST/ALT >3x ULN). For HoFH, separate criteria apply. Continuation requires positive clinical response (LDL‑C reduction).LDL‑C >=70 mg/dL

    Initial 6 months; continuation 12 months.

    Cushing's disease (Signifor)

    Signifor (pasireotide) for Cushing's disease initial coverage:

    Signifor initial: (1) Diagnosis of pituitary Cushing's disease; (2) pituitary surgery is not an option or has not been curative. Prescribed by or in consultation with an endocrinologist. Age ≥18 years. Initial and reauth durations commonly 12 months; reauth requires documented positive clinical response (e.g., reduction in 24‑hour urinary free cortisol).

    Pulmonary arterial hypertension

    Sildenafil (oral) coverage for PAH and Raynaud's phenomenon:

    Sildenafil (PAH): (1) Diagnosis of PAH WHO Group I with NYHA Functional Class II–IV; (2) diagnosis confirmed by catheterization or echocardiography; (3) mean pulmonary artery pressure ≥25 mm Hg at rest or ≥30 mm Hg with exertion. Prescribed by cardiologist or pulmonologist. Exclusion: concomitant nitrate use.mPAP >=25 mm Hg

    Coverage indefinite where listed.

    Skyrizi maintenance

    Skyrizi (risankizumab) coverage for indications including PsO, PsA, CD, UC:

    Skyrizi maintenance (CD/UC): For Crohn's disease and ulcerative colitis: maintenance use of SC Skyrizi only following IV induction as specified; prescriber specialty and age restrictions apply; Part B may apply for MA‑PD beneficiaries.

    Maintenance per product labeling; coverage durations per policy.

    ATTR-CM (Vyndaqel)

    Vyndaqel (tafamidis) coverage for ATTR‑CM initial and reauthorization:

    ATTR‑CM (Vyndaqel) initial: (1) Diagnosis of transthyretin‑mediated amyloidosis with cardiomyopathy confirmed by TTR mutation, biopsy, or combined imaging with exclusion of light‑chain amyloidosis; (2) history of heart failure with ≥1 prior hospitalization OR clinical signs/symptoms of HF; (3) NYHA Functional Class I–III. Prescribed by or in consultation with cardiologist. Initial/reauth duration commonly 12 months; reauth requires continued NYHA I–III and positive clinical response.NYHA I-III

    ANCA-associated vasculitis (Tavneos)

    Tavneos (avacopan) coverage for severe active ANCA‑associated vasculitis (GPA/MPA):

    Tavneos initial: (1) Diagnosis of severe active ANCA‑associated vasculitis (GPA or MPA); (2) used as adjunct to standard therapy including glucocorticoids. Prescribed by or in consultation with nephrologist, pulmonologist, or rheumatologist. Initial coverage 6 months; reauth 1 year requires sustained remission by BVAS.

    Teriparatide/Forteo osteoporosis

    Teriparatide/Forteo coverage for osteoporosis indications:

    Teriparatide/Forteo initial (HGO/PMO): Primary/hypogonadal osteoporosis or postmenopausal osteoporosis: diagnosis plus severe/high fracture risk defined by history of multiple vertebral fractures OR BMD T‑score ≤ ‑2.5 OR history of osteoporotic low‑trauma fracture AND inadequate response or intolerance to bisphosphonates or hormone therapy as applicable. Glucocorticoid‑induced osteoporosis: prednisone ≥5 mg daily for ≥3 months AND inadequate response/intolerance to alternative therapies. Prescriber documents risk/benefit. Reauth limits cumulative lifetime therapy to ≤24 months for parathyroid hormones with specified exceptions.BMD T-score <= -2.5; prednisone >=5 mg/day for >=3 months

    Coverage durations vary; reauth per policy.

    Rinvoq prior therapy requirements

    Rinvoq (upadacitinib) coverage across multiple rheumatologic and GI indications:

    Rinvoq required prior therapy: For RA, PsA, UC, CD and other labeled indications: diagnosis of the condition and inadequate response or intolerance to specified conventional DMARDs and typically one or more TNF inhibitors (or documentation that trials are inappropriate). Exclusion: concurrent use with other biologic DMARDs, other JAK inhibitors, or potent immunosuppressants.age limits vary by indication

    Prescribed by relevant specialist; coverage duration often indefinite.

    Biologic sequencing requirements

    Multiple biologic agents require failure or intolerance to specified prior agents

    Biologic sequencing requirements: For indications such as AS, PsA, RA, PsO, UC, CD and similar disorders: inadequate response or intolerance to two or more listed biologics or specified alternative agents (examples include adalimumab, etanercept, secukinumab, ustekinumab, tofacitinib, upadacitinib, Skyrizi) OR documentation that trials are inappropriate. Prescriber specialty and age restrictions apply as indicated.typically two failed agents for many indications

    Concurrent biologic therapy excluded.

    Primary or Hypogonadal Osteoporosis (HGO) — Initial

    Covered when ALL of the following are met

    HGO initial criteria: (1) Diagnosis of hypogonadal or primary osteoporosis in men; (2) severe osteoporosis or high/very high fracture risk defined by multiple vertebral fractures OR BMD T‑score ≤ ‑2.5 OR history of osteoporotic fracture; (3) inadequate response or intolerance to bisphosphonates or hormone replacement therapy. Prescriber documents indications and prior therapy trials.

    Age ≥18; coverage per policy.

    Postmenopausal Osteoporosis (PMO) — Initial and Reauth

    Covered when ALL of the following are met

    PMO initial criteria: (1) Diagnosis of postmenopausal osteoporosis; (2) severe osteoporosis or high/very high fracture risk defined by multiple vertebral fractures OR BMD T‑score ≤ ‑2.5 OR history of osteoporotic fracture; (3) inadequate response or intolerance to at least one alternative (bisphosphonates, HRT, SERMs, denosumab) as applicable. Reauth limited by cumulative lifetime therapy rules for certain agents.

    Coverage duration typically 12 months; reauth per policy.

    Glucocorticoid-Induced Osteoporosis (GCO) — Initial

    Covered when ALL of the following are met

    GCO initial criteria: (1) Diagnosis of glucocorticoid‑induced osteoporosis; (2) Prednisone ≥5 mg daily for ≥3 months; (3) Inadequate response or intolerance to one alternative (bisphosphonates, hormone therapy, SERMs, or denosumab).prednisone >=5 mg/day for >=3 months

    Reauth requires documented clinical benefit.

    Hypogonadism (HG) — New Starts and Continuation

    Covered when ALL of the following are met

    Hypogonadism (HG) new starts: (1) Attestation that diagnosis confirmed by two early morning total testosterone <300 ng/dL on separate occasions, normal prolactin, and compatible symptoms; (2) negative history of prostate/breast cancer OR if history of prostate cancer, stable PSA ≤4 ng/dL for 2 years and documented risk–benefit assessment. Age restrictions apply (12+ for some formulations, 18+ for others).two early morning total testosterone <300 ng/dL

    Continuation requires ongoing documentation per policy.

    TREMFYA (and other biologics) — Psoriasis, Psoriatic Arthritis, UC, CD

    Covered when criteria per indication are met

    TREMFYA and other biologics — PsO/PsA/UC/CD: Diagnosis per indication and inadequate response or intolerance to the required number/type of prior agents (often two specified biologic/systemic agents such as Cosentyx, Enbrel, Adalimumab, Skyrizi, Ustekinumab, Rinvoq, Xeljanz). No concurrent biologic DMARDs. Prescribed by appropriate specialist; reauth requires positive clinical response.prior trials as specified

    Coverage durations vary (often indefinite).

    Pulmonary Arterial Hypertension (PAH) — multiple products

    Covered when ALL of the following are met

    PAH (multiple products): (1) Diagnosis of PAH WHO Group I with NYHA Class II–IV; (2) diagnosis confirmed by right‑heart catheterization or echocardiography with mean PAP ≥25 mm Hg at rest (or >30 with exertion); (3) inadequate response or intolerance to class‑specific agents as applicable per product; (4) prescribed by or in consultation with cardiologist or pulmonologist. Initial coverage often 6 months; reauth 12 months with stabilization/improvement documented.mPAP >=25 mm Hg

    Exclusion: combination with prostanoid/prostacyclin analogue for some products.

    Vowst — Prevention of recurrent C. difficile infection (PCDI)

    Covered when ALL of the following are met

    Vowst PCDI criteria: (1) Diagnosis of recurrent C. difficile infection with positive stool toxin or toxigenic C. difficile and symptomatic diarrhea (≥3 loose stools/day for ≥2 consecutive days); (2) history of ≥2 recurrent CDI episodes within 12 months; (3) completed at least 10 days of oral vancomycin or fidaxomicin 2–4 days prior to initiating Vowst; (4) completed recommended bowel prep the day before and ≥8 hours prior to instillation; (5) prior episode under control (e.g., <3 unformed stools/day for ≥2 consecutive days). Prescribed by gastroenterologist or infectious disease specialist.

    Coverage duration: 14 days; 1 course limit.

    Xifaxan — multiple indications

    Covered when indication‑specific criteria are met

    Xifaxan — HE/IBS‑D/SBBO: Prophylaxis for hepatic encephalopathy: diagnosis of hepatic disease with risk for HE and inadequate response or intolerance to lactulose. IBS‑D: diagnosis of IBS‑D with inadequate response or intolerance to BOTH a TCA or SSRI AND dicyclomine, and limit to ≤3 total courses (42 days). SBBO/SIBO: diagnosis with recurrence documentation for reauth. Prescriber documents required prior therapies and diagnostic testing.course limits (≤3 total courses/42 days)

    Coverage durations per indication (HE indefinite; IBS‑D 2 weeks per course).

    Xolair (omalizumab) — asthma, chronic urticaria, nasal polyps

    Covered when ALL of indication‑specific criteria are met

    Xolair — Moderate to severe persistent allergic asthma (PAA): (1) Diagnosis of moderate to severe persistent allergic asthma; (2) positive skin test or in vitro reactivity to a perennial aeroallergen; (3) baseline serum IgE 30–1300 IU/mL; (4) inadequate response or inability to tolerate high‑dose ICS+LABA. Prescribed by allergist/immunologist or pulmonologist; age ≥6. Reauth requires documented positive clinical response.IgE 30–1300 IU/mL

    Coverage durations per policy; concurrent biologic therapy excluded.

    Xolair — Chronic urticaria (CU): (1) Diagnosis of chronic urticaria; (2) inadequate response/contraindication/intolerance to one maximally tolerated second‑generation H1 antihistamine plus adjuncts as listed; (3) will be used concurrently with H1 antihistamine unless contraindicated. Prescriber: allergist/immunologist or dermatologist; age ≥12.

    Reauth requires reduction in itching/hives from baseline.

    Xolair — Nasal polyps (NP): (1) Diagnosis of nasal polyps; (2) will use concurrently with intranasal corticosteroid; (3) inadequate response or intolerance to intranasal corticosteroid; (4) baseline serum IgE ≥30 IU/mL. Prescriber: allergist/ENT/pulmonologist; age ≥18.IgE >=30 IU/mL

    Reauth requires positive clinical response (reduced NPS/NCS).

    Xolair — IgE‑mediated food allergy (IMFA): (1) Diagnosis and clinical history of IgE‑mediated food allergy OR history of severe allergic reaction/anaphylaxis to food; (2) used with food allergen avoidance; (3) baseline total IgE 30–1850 IU/mL and dosing per IgE and body weight. Prescriber: allergist/immunologist; age ≥1.IgE 30–1850 IU/mL

    Reauth requires documented positive clinical response and continued avoidance.

    Initial Therapy

    Covered when ALL of the following are met for each indication

    Initial Therapy (selected biologics): Initial approval requires diagnostic confirmation, documentation of prior therapy failures or intolerance as specified per indication (e.g., trials of topical therapies for AD, inhaled/other controllers for asthma, prior systemic/biologic agents for rheumatologic and GI indications), prescriber specialty, and age limits where applicable.

    Initial coverage durations typically 6–12 months per product; reauth criteria require documented clinical benefit.

    Continuation/Reauthorization

    Reauthorization covered when ALL of the following are met for each indication

    Reauthorization general: Documentation of objective positive clinical response since last authorization (examples: reduction in exacerbations, improved FEV1, decreased rescue medication use, reduction in itching or hives, improved nasal polyp scores), ongoing adherence to concomitant required therapies, and prescriber re‑evaluation as required.

    Reauth durations commonly 12 months; specifics vary by product.

    Concurrent therapy with another biologic disease-modifying anti-rheumatic drug (biologic DMARD) or other tumor necrosis factor antagonist is an explicit exclusion across multiple biologic product policies. Requests that document concomitant use of two biologic agents for the same or overlapping immune-mediated indication (for example RA, PsA, AS, JIA, PsO, CD, UC) do not meet the coverage criteria and are subject to denial unless the policy expressly permits combination therapy and documents clinical justification. Prescriber specialty and prior-therapy requirements still apply for eligible single-biologic therapy requests.

    Administration of live or live-attenuated vaccines is an exclusion when a member is receiving immunosuppressive doses of certain therapies (for example, high-dose ACTHAR/H.P. Acthar Gel). Providers should not co-administer live vaccines to members on immunosuppressive regimens and must document vaccination history; requests that indicate live vaccine administration while receiving immunosuppressive doses will be excluded from coverage.

    Multiple rheumatology and dermatology biologic policies specify that concurrent therapy with other biologic DMARDs or TNF antagonists is an exclusion. For conditions such as ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and related indications, a request that documents ongoing treatment with another biologic agent will not meet medical necessity and is a denial trigger unless an indication-specific exception is documented.

    For tadalafil prescribed for benign prostatic hyperplasia (BPH), coverage is excluded when the member is using concomitant nitrates. Documented concurrent nitrate therapy (any formulation) is an exclusion due to known hemodynamic interactions and will result in non-coverage.

    Policies for biologics and for CGRP inhibitors consistently prohibit overlapping biologic treatments. Specifically, concurrent use of any other biologic agent is an exclusion for many indications; for CGRP products, documentation of concomitant use with another injectable CGRP inhibitor (or other biologic for the same indication) is a basis for denial. Providers must document cessation of prior biologic therapy before initiating a different biologic unless the policy indicates otherwise.

    Growth-related therapies (e.g., for growth hormone gene deletion or severe primary IGF-1 deficiency) include exclusions such as known or suspected malignancy, evidence of closed epiphyses, and concurrent growth hormone therapy. Requests lacking endocrinologist documentation or demonstrating one of these exclusion conditions will not meet coverage criteria.

    Use of mifepristone for hyperglycemia in Cushing syndrome is explicitly excluded during pregnancy. Prescribers must confirm pregnancy status and avoid initiating mifepristone in pregnant members; documentation of pregnancy is a contraindication to coverage.

    For Nucala (mepolizumab) and similar agents for asthma/allergic conditions, concurrent therapy with any other biologic for asthma/allergic conditions (examples: benralizumab, dupilumab, omalizumab) is an exclusion. Requests must show that no other biologic is being administered for the same disease state to be considered for approval.

    Nuedexta (dextromethorphan/quinidine) is excluded in the presence of documented prolonged QT interval, congenital long QT syndrome, or a history of torsades de pointes based on an ECG or other cardiac test. Such cardiac findings are contraindications and will trigger denial.

    Olumiant (baricitinib) coverage for rheumatoid arthritis and alopecia areata excludes concurrent use of other biologic DMARDs, JAK inhibitors, or potent immunosuppressants. Requests showing overlap with these therapies will not meet medical necessity and may be denied.

    Orkambi (lumacaftor/ivacaftor) coverage is limited to cystic fibrosis patients with the specified genotype; an exclusion applies for CF diagnoses other than those indicated (for example, patients not homozygous for F508del). Confirmatory CFTR mutation testing and genotype documentation are required for coverage consideration.

    Initial Therapy Criteria (top-level initial approvals)

    Continuation / Reauthorization Criteria

    Step Therapy Requirements

    Drug / IndicationStep requirement
    Aimovig (CGRP inhibitor) — Migraine (episodic or chronic)
    Trial and inadequate response or intolerance to TWO specified oral prophylactic medications (each ~4‑week trial) such as topiramate; divalproex/valproic acid; a beta‑blocker (metoprolol, propranolol, timolol, atenolol, nadolol); a tricyclic (amitriptyline, nortriptyline); an SNRI (venlafaxine, duloxetine); or candesartan before approval. Documentation of concomitant use with another injectable CGRP inhibitor is excluded.
    DrugStep requirement
    Auvelity (for Major Depressive Disorder)
    Prior inadequate response or intolerance to TWO formulary antidepressants (examples: bupropion, venlafaxine XR, sertraline) required for new starts.
    Lybalvi (schizophrenia/related indications)
    Trial of TWO generic formulary antipsychotics required for new starts.
    Caplyta (schizophrenia, bipolar depression)
    Inadequate response or intolerance to TWO generic antipsychotics for schizophrenia, or to TWO medications indicated for bipolar depression, required prior to approval.
    ContextRequired prior medication trials
    Rheumatology biologics (general) — e.g., Enbrel, Cimzia, others
    Inadequate response or intolerance to specified prior conventional DMARD(s) and/or biologic agents as listed per indication — commonly failure of ONE to TWO prior agents (examples: methotrexate or ONE DMARD for RA; two listed biologics for other indications). Concurrent therapy with other biologic DMARDs is excluded.
    Biologic sequencing for PsO/PsA/AS/UC/CD
    Typically requires inadequate response or intolerance to TWO specified biologic or systemic agents (examples: adalimumab, etanercept, Cosentyx, Skyrizi, ustekinumab) or documentation that trials are inappropriate before approval of another biologic.
    Rheumatology areaStep requirement / GLP-1 note
    Rheumatology biologics (RA, AS, PsA, PJIA)
    Inadequate response or intolerance to TWO specified prior agents (examples include adalimumab, etanercept, Rinvoq, Xeljanz) or documentation trials are inappropriate; concurrent biologic DMARD therapy is excluded.
    GLP‑1 related step (note: GLP‑1 class elsewhere)
    For GLP‑1 receptor agonists used in diabetes/weight management, initial approval requires inadequate response or intolerance to a minimum 90‑day supply of TWO preferred GLP‑1 products (e.g., Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza) per the GLP‑1 step rule.
    DrugStep requirement
    Nexletol / Nexlizet (HeFH / Primary hyperlipidemia / CVD high risk)
    Prior trial of at least 8 weeks of a maximally tolerated statin AND at least 8–12 weeks of ezetimibe (or documented contraindication/intolerance) before initial approval; documentation of LDL‑C thresholds required.
    Drug classStep requirement
    GLP‑1 receptor agonists (listed preferred brands)
    Initial approval requires inadequate response or intolerance to a minimum 90‑day supply of TWO preferred GLP‑1 products (examples: Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza) with medical record documentation.
    Drug / UseStep requirement
    Nurtec (rimegepant) — Preventive use
    Failure or intolerance to TWO 4‑week trials of specified oral prophylactic medications for migraine prevention required prior to approval for preventive use. (Acute use has separate single‑triptan failure rule.)
    Condition / DrugStep requirement
    Onychomycosis (topical/systemic agents) — e.g., tavaborole / oral antifungals
    Diagnosis confirmed by KOH, culture, or histology AND documentation that condition causes debility/ADL disruption AND inadequate response or intolerance to BOTH: oral generic terbinafine AND (oral generic itraconazole OR topical generic ciclopirox) prior to approval.
    Drug (Indication)Required prior therapies
    Eltrombopag (Promacta) — Chronic ITP
    Baseline platelet count <30,000/mcL and inadequate response or intolerance to ONE of: corticosteroids, immune globulin, or splenectomy prior to approval; continuation requires documented platelet response.
    General ruleRequired documentation / trial
    Required trials of alternative therapies for biologics/specialty agents
    Documented inadequate response or intolerance to specified alternative agents (number and agents vary by indication — commonly failure of one or two TNF inhibitors or other listed biologics/systemic agents) is required, or provide documentation why trials are inappropriate. Concurrent use of other biologic DMARDs/JAK inhibitors is excluded.
    Indication groupStep requirement
    Biologics for Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease (e.g., Tremfya, Yesintek, Skyrizi)
    Inadequate response or intolerance to TWO specified biologic or systemic agents (examples listed per indication such as Adalimumab, Enbrel, Cosentyx, Skyrizi, Ustekinumab, Rinvoq, Xeljanz) or documentation that trials are inappropriate before approval; concurrent biologic therapy excluded.
    Drug / IndicationStep requirement
    Xifaxan (rifaximin) — IBS‑D
    Inadequate response or intolerance to BOTH: (A) ONE tricyclic antidepressant or SSRI AND (B) dicyclomine prior to approval; limit to ≤3 total courses (42 days total).
    ConditionStep requirement
    Chronic urticaria
    Prior inadequate response, contraindication, or intolerance to ONE second‑generation H1 antihistamine at maximally tolerated dose plus consideration of adjuncts (leukotriene receptor antagonist, H2 antagonist, switching antihistamines, systemic steroids or cyclosporine) required before approval; will be used concurrently with an H1 antihistamine unless contraindicated.
    DrugStep / prior therapy requirement
    Promacta (eltrombopag) — continuation rules (general)
    Continuation allowed when ONE of listed continuation scenarios is met (e.g., increased platelet count sufficient to avoid clinically important bleeding) or when specific interferon/antiviral context criteria apply; initial approval requires prior standard therapies tried and failed or not tolerated.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required — follow product-specific PA criteria

    Many drugs in this formulary require prior authorization. Providers must submit indication-specific documentation (diagnosis confirmation), prior trial(s) or intolerance to alternative therapies where required, prescriber specialty and age information, and any other required medical information listed for the product requested. Follow the individual product entries for exact PA criteria and required supporting documentation.

    • Diagnosis confirmation required per product-specific criteria
    • Documentation of prior therapy trials or documented intolerance when specified
    • Prescriber specialty and age restrictions must be provided when listed
    • Additional required medical information (labs, imaging, susceptibility results) as specified per drug
    Prior Authorization

    Austedo prior authorization requirements

    Austedo and Austedo XR require prior authorization with documentation of the specific sleep disorder diagnosis. Narcolepsy and OSAHS generally require confirmation by a sleep study unless the prescriber documents why a sleep study is not feasible. Prescriptions should be from or in consultation with a neurologist or sleep specialist.

    • Narcolepsy: sleep study confirmation unless infeasible
    • OSAHS: sleep study confirmation with ≥5 obstructive events/hour plus symptoms unless infeasible
    • Prescribed by or in consultation with a neurologist or sleep specialist
    Prior Authorization

    Cayston prior authorization specifics

    Cayston PA requires documentation of a diagnosis of cystic fibrosis, evidence of Pseudomonas aeruginosa in the lungs with susceptibility showing sensitivity to aztreonam, and FEV1 between 25% and 75% predicted. Prescriptions must be by or in consultation with a pulmonologist, infectious disease specialist, or CF center specialist.

    • CF diagnosis and Pseudomonas aeruginosa evidence with aztreonam susceptibility
    • FEV1 documented between 25%–75% predicted
    • Prescriber: pulmonologist, infectious disease specialist, or CF center specialist
    Prior Authorization

    Dupixent prior authorization specifics

    Dupixent prior authorization requires indication-specific documentation: e.g., for atopic dermatitis an inadequate response/intolerance to one medium+ potency topical steroid or topical tacrolimus/pimecrolimus/crisaborole; for asthma meet eosinophil/exacerbation criteria and concurrent medium–high dose ICS plus another controller; for EoE provide biopsy with ≥15 eosinophils/HPF and prior PPI or topical steroid trial. Concurrent use with other biologic agents is excluded.

    • AD: inadequate response/intolerance to specified topical therapies
    • Asthma: eosinophil thresholds and exacerbation history, plus use with medium–high dose ICS + another controller
    • EoE: ≥15 eos/HPF, symptoms, exclusion of other causes, and failed ≥8-week PPI or topical esophageal corticosteroid
    • Concurrent biologic therapy is an exclusion
    Prior Authorization

    PA submissions — include indication-specific documentation

    Prior authorization submissions must include the indication-specific documentation listed in the product entry: diagnosis confirmation, required prior therapy trials or documented intolerance, age and prescriber specialty information, and any required objective test results or labs.

    • Provide required prior therapy trials or justification why trials are inappropriate
    • Include age and prescriber specialty per product requirements
    • Attach objective supporting data (labs, imaging, pulmonary function, biopsy, susceptibility testing) when specified
    Prior Authorization

    Growth therapy PA duration and annual re-evaluation

    Growth-related therapies are authorized for 12 months for initial and continuation approvals; continuation typically requires annual clinical re-evaluation by the treating endocrinologist and documentation of increased growth velocity or other indication-specific response measures.

    • Initial and continuation PA durations: 12 months
    • Annual clinical re-evaluation by treating endocrinologist required for continuation
    • Continuation requires objective evidence of response (e.g., increased growth velocity)
    Prior Authorization

    High-dose opioid continuation — documentation required

    Continuing high-dose opioid therapy (morphine-equivalent ≥90 mg/day) requires documentation that the member's pain was assessed within the last 6 months, there is clinically meaningful improvement in pain and function outweighing risks, and the member is not being treated for substance abuse.

    • Pain assessment within prior 6 months
    • Clinically meaningful improvement in pain/function documented
    • No current treatment for substance abuse
    Prior Authorization

    Lidocaine patch prior authorization

    Lidocaine 5% patches require prior authorization with documentation of the qualifying diagnosis (post-herpetic neuralgia or diabetic peripheral neuropathy) per the product entry.

    • Document diagnosis of PHN or DPN
    • Provide any other required supporting information as listed in the product entry
    Prior Authorization

    Livtencity (CMV) prior authorization requirements

    Livtencity (letermovir) prior authorization requires documentation of CMV infection/disease in a hematopoietic stem cell or solid organ transplant recipient, failure or intolerance to at least 2 weeks of IV ganciclovir, oral valganciclovir, IV foscarnet, or IV cidofovir, and the member must weigh ≥35 kg and be ≥12 years old.

    • Diagnosis of CMV infection/disease in transplant recipient
    • Inadequate response or intolerance to ≥2 weeks of listed antivirals
    • Age ≥12 years and weight ≥35 kg
    Prior Authorization

    Nuedexta prior authorization and cardiac exclusion

    Nuedexta for pseudobulbar affect requires PA with documentation of PBA and an underlying qualifying neurologic condition; providers must note the exclusion for prolonged QT, congenital long QT syndrome, or torsades de pointes.

    • Document diagnosis of PBA and qualifying neurologic condition (e.g., ALS, MS, stroke, traumatic brain injury)
    • Provide prescriber specialty (neurologist or psychiatrist) as requested
    • Do not approve if prolonged QT, congenital long QT syndrome, or torsades de pointes is documented
    Prior Authorization

    Onychomycosis — PA documentation and prior therapy requirement

    Onychomycosis prior authorization requires confirmatory diagnostic testing (KOH, culture, or histology), documentation that the condition causes debility or ADL disruption, and evidence of inadequate response or intolerance to oral terbinafine and either oral itraconazole or topical ciclopirox before approval.

    • Confirm diagnosis with KOH, culture, or histology
    • Document functional impact or ADL disruption
    • Provide prior treatment trials showing failure or intolerance to required agents
    Prior Authorization

    PAH agents — PA and specialist documentation

    PA for pulmonary arterial hypertension agents requires documentation of WHO Group I PAH with NYHA Functional Class II–IV, confirmatory right-heart catheterization or echocardiography including mean pulmonary artery pressure ≥25 mm Hg at rest (or >30 with exertion), and specialist involvement; initial approvals commonly 6 months with continuation 12 months contingent on stabilization or improvement.

    • PAH WHO Group I diagnosis with NYHA II–IV documented
    • Confirmatory catheterization or echocardiography and mPAP ≥25 mm Hg at rest
    • Prescribed by or in consultation with a cardiologist or pulmonologist
    • Initial coverage typically 6 months; continuation 12 months with stabilization/improvement
    Prior Authorization

    Praluent prior authorization — LDL and statin trial documentation

    Praluent prior authorization requires LDL-C values meeting the specified thresholds after a minimum 8-week trial of at least moderate-intensity statin therapy, or documented statin intolerance per criteria. Initial authorizations are commonly 6 months with 12-month continuation contingent on positive clinical response.

    • LDL‑C ≥70 mg/dL after ≥8-week moderate‑intensity statin trial (or meet HoFH thresholds as specified)
    • Document statin intolerance per listed CK/AST/ALT or clinical criteria if applicable
    • Initial 6 months; continuation 12 months with evidence of LDL‑C reduction
    Documentation Required

    Promacta continuation — document clinical response

    Promacta (eltrombopag) continuation requires evidence of a positive clinical response appropriate to the indication, such as an increase in platelet count sufficient to avoid clinically important bleeding; continuation durations vary by indication (commonly 12 months).

    • Provide objective evidence of platelet count increase for ITP
    • For hepatitis C/interferon-related use, meet specified interferon therapy continuation criteria
    Note

    Skyrizi induction required before maintenance; Part B note

    Skyrizi maintenance dosing for Crohn's disease and ulcerative colitis is approved only following IV induction; note that Part B may apply for MA‑PD beneficiaries for infusion-related portions of therapy.

    • SC maintenance use permitted only after IV induction for CD/UC
    • Site-of-care/benefit (Part B vs Part D) may apply for MA‑PD beneficiaries
    Prior Authorization

    Osteoporosis PA — severity, prior therapy, and lifetime limits

    Osteoporosis (PMO/OSTm) prior authorization requires member ≥18 years and documentation of severe osteoporosis or high fracture risk (e.g., multiple vertebral fractures or BMD T-score ≤ -2.5) and prior inadequate response or intolerance to listed therapies; cumulative lifetime therapy limits may apply to certain agents on reauthorization.

    • Document BMD T-score ≤ -2.5 or history of osteoporotic fracture or multiple vertebral fractures
    • Provide prior therapy trials or intolerance documentation
    • Cumulative lifetime therapy limits (e.g., 2 years) apply for certain agents on reauth
    Prior Authorization

    Biologics (PsO/PsA/UC/CD) — PA and sequencing requirements

    Biologics for psoriasis, psoriatic arthritis, UC, and Crohn's require prior authorization documenting diagnosis, specialist prescribing/consultation, and inadequate response or intolerance to the specified alternative agents (typically two agents or as listed); concurrent use with other biologic DMARDs or TNF antagonists is excluded.

    • Document failure/intolerance to required prior biologic or systemic agents (typically two)
    • Prescriber specialty (dermatology, rheumatology, or gastroenterology) per indication
    • Concurrent biologic DMARD therapy is excluded
    Prior Authorization

    Prior authorization — general provider actions

    Prior authorization is required for many specialty agents; providers must supply indication‑specific documentation, required prior therapy trials or intolerance evidence, age and prescriber specialty, and any objective tests or labs specified in the product entry.

    • Follow individual product entries for the exact list of required documents
    • Include age, prescriber specialty, and objective test results when requested
    • If the product page is an index entry, consult the full product policy for PA rules
    Note

    Index-only — consult individual product pages for PA rules

    This index is an index-only section and does not contain prior authorization rules. Providers must review the individual drug policy pages referenced for each product to find PA requirements and documentation instructions.

    • Index entries list product names and page references only
    • Locate the full product policy page for PA criteria and required documentation
    Step Therapy

    Step therapy used — document required prior trials

    Step therapy is applied to selected drugs. For migraine CGRP inhibitors and other listed agents, prior trials of specified oral prophylactic medications or alternative agents must be documented before approval.

    • CGRP inhibitors: document trials of specified oral prophylactic medications per migraine frequency
    • Follow product-specific step therapy tables for required agents and durations
    Step Therapy

    Auvelity — step therapy requirement

    Auvelity for major depressive disorder requires documentation of inadequate response or intolerance to two formulary antidepressants prior to approval.

    • Document trials and inadequate response or intolerance to two formulary antidepressants
    Step Therapy

    Lybalvi — step therapy requirement

    Lybalvi new starts require documentation of trials of two generic formulary antipsychotics before approval.

    • Provide records of two generic antipsychotic trials and inadequate response or intolerance
    Step Therapy

    Caplyta — step therapy requirement

    Caplyta requires inadequate response or intolerance to two antipsychotics (schizophrenia) or two medications for bipolar depression as applicable prior to approval.

    • Document two failed or intolerant antipsychotic trials (or bipolar depression alternatives) for new starts
    Step Therapy

    Required prior medication trials — document failures/intolerance

    Prior medication trials are commonly required: many indications require documented inadequate response or intolerance to specified alternative therapies (examples include two prophylactic agents for migraine or one DMARD for RA) before specialty therapy is approved.

    • Document specific prior agents and trials per indication
    • Provide justification if trials are inappropriate
    Step Therapy

    Rheumatology biologics — step requirements

    Rheumatology biologics often require inadequate response or intolerance to oral methotrexate or specific prior biologics (e.g., adalimumab, etanercept) before coverage; prescriber specialty (rheumatologist) is typically required.

    • Document methotrexate and other prior therapy failures/intolerance as specified
    • Prescribed by or in consultation with a rheumatologist when listed
    Step Therapy

    Nexletol/Nexlizet — statin and ezetimibe step requirements

    Nexletol/Nexlizet initial approval requires at least an 8‑week trial of maximally tolerated statin therapy and 8–12 weeks of ezetimibe when applicable, with LDL‑C documentation per the policy.

    • Document ≥8 weeks of statin therapy at maximally tolerated dose
    • Document ezetimibe trial of 8–12 weeks or provide contraindication/intolerance
    • Include LDL‑C values within required timeframe
    Step Therapy

    GLP‑1 step therapy — two preferred GLP‑1 trials required

    GLP‑1 receptor agonist coverage requires documentation of type 2 diabetes and inadequate response or intolerance to a minimum 90‑day supply of two preferred GLP‑1 brands before approval.

    • Submit diagnostic labs confirming T2DM (A1C/FPG/OGTT) and medical records
    • Provide evidence of two 90‑day trials of preferred GLP‑1s with inadequate response or intolerance
    Step Therapy

    Nurtec — step therapy requirements (acute and preventive)

    Nurtec preventive use requires failure or intolerance to two 4‑week trials of listed prophylactic medications prior to approval; acute use requires failure or intolerance to one generic triptan.

    • Preventive: document two 4‑week prophylactic trials with inadequate response/intolerance
    • Acute: document inadequate response/intolerance to one generic triptan
    Step Therapy

    Antipsychotic step requirements — aripiprazole products

    Aripiprazole products require documentation of inadequate response or intolerance to aripiprazole and additional generic formulary antipsychotics depending on indication (e.g., schizophrenia, adjunctive MDD, autism irritability, Tourette's) before approval.

    • Document trials of aripiprazole and the other required generic antipsychotic(s)
    • Provide indication-specific supporting documentation
    Step Therapy

    Required trials of alternative therapies for biologics/specialty agents

    Many biologic and specialty agents require trials of specified alternative therapies and documentation of inadequate response or intolerance (e.g., required trials of TNF inhibitors or other named biologics) before approval.

    • Provide records of the specified prior biologic/systemic agent trials and outcomes
    • If trials are inappropriate, provide clinical justification
    Step Therapy

    Xifaxan — step requirements and quantity limits for IBS‑D

    Xifaxan for IBS‑D requires documentation of inadequate response or intolerance to both (A) one tricyclic antidepressant or SSRI and (B) dicyclomine, and course limits apply (≤3 total courses/42 days).

    • Document failure/intolerance to one TCA or SSRI and to dicyclomine
    • Adhere to quantity limit: up to 3 courses (42 days total)
    Step Therapy

    Chronic urticaria — step therapy requirement

    For chronic urticaria, prior inadequate response, contraindication, or intolerance to one second‑generation H1 antihistamine at maximally tolerated dose plus adjuncts (leukotriene receptor antagonist, H2 antagonist, switching antihistamines, systemic steroids, or cyclosporine) is required before approval.

    • Document failure/intolerance/contraindication to one maximally tolerated second‑generation H1 antihistamine
    • Document trials of or consideration of listed adjunct therapies
    Note

    Index-only — no step therapy rules listed here

    No step therapy rules are present in this index excerpt; consult the individual product policy pages for step therapy requirements.

    • Index entries only — see full product pages for ST rules
    Denial Risk

    Denial risk — missing prior authorization

    Failure to obtain a required prior authorization may result in the plan not covering the drug. Providers should obtain PA before dispensing to avoid coverage denial.

    • Submit PA prior to fill to avoid non‑coverage
    • Follow product-specific PA instructions and provide requested documentation
    Denial Risk

    Cayston — denial triggers for missing microbiology or FEV1 criteria

    Cayston requests lacking evidence of Pseudomonas aeruginosa in the lungs, susceptibility showing sensitivity to aztreonam, or with FEV1 outside the required 25%–75% predicted range may be denied.

    • Ensure documented Pseudomonas culture or other evidence and aztreonam susceptibility
    • Provide FEV1 within 25%–75% predicted
    Denial Risk

    Biologic therapy denial triggers — concurrent use or missing prior trials

    Concurrent therapy with other biologic DMARDs or TNF antagonists, or failure to document required prior therapy trials, may trigger denial for multiple biologic agents (e.g., Cimzia, Cosentyx, other listed products).

    • Do not request approval if member is on another biologic DMARD unless policy explicitly allows
    • Provide documentation of required prior biologic or systemic therapy trials
    Denial Risk

    Denial risk — concurrent biologic therapy excluded

    Concurrent therapy with any other biologic agent is an exclusion for multiple indications; do not request overlapping biologic therapies as they will be denied.

    • Confirm member is not receiving another biologic for the same or related indication
    • If concurrent therapy is clinically necessary, document rationale and check policy exceptions
    Denial Risk

    Denial trigger — concomitant injectable CGRP inhibitors

    For CGRP inhibitors and related migraine biologics, documented concomitant use of another injectable CGRP inhibitor is an exclusion and may result in denial.

    • Do not co‑prescribe multiple injectable CGRP inhibitors
    • Provide medication history showing absence of other injectable CGRP agents
    Denial Risk

    High‑dose opioid prerequisite — denial risk if prerequisites missing

    New-to‑high‑dose opioid requests that do not document cancer‑related pain or, for chronic non‑cancer pain, opioid tolerance and prior evaluation for non‑opioid pharmacologic treatments may be denied.

    • For new high‑dose starts, document cancer pain OR opioid tolerance AND prior non‑opioid evaluation
    • Provide evidence of opioid tolerance per the policy example dosing
    Denial Risk

    Growth disorder denial triggers — missing diagnostic thresholds or specialist involvement

    For growth hormone gene deletion or severe primary IGF‑1 deficiency, requests missing required diagnostic thresholds (e.g., SDS values) or lacking endocrinologist involvement may be denied.

    • Include height and IGF‑1 SDS values when applicable
    • Prescriber should be an endocrinologist or document specialist consultation
    Denial Risk

    Nuedexta — cardiac exclusion may cause denial

    Nuedexta is excluded for patients with documented prolonged QT interval, congenital long QT syndrome, or torsades de pointes on cardiac testing; presence of these findings may trigger denial.

    • Provide ECG/cardiac test results; do not approve if prolonged QT or related conditions are present
    Denial Risk

    Posaconazole — denial risk if prior voriconazole trial not documented

    For posaconazole prophylaxis, failure to document an inadequate response or intolerance to voriconazole when required may result in denial of posaconazole for prophylaxis.

    • For prophylaxis use, document prior voriconazole failure/intolerance when specified
    • Include indication and relevant specialist consultation (ID/transplant)
    Denial Risk

    Nexletol/Nexlizet — LDL and prior therapy denial triggers

    Nexletol/Nexlizet requests lacking documentation of required LDL‑C thresholds or failure/intolerance to statins and ezetimibe per the policy may be denied.

    • Provide LDL‑C values and evidence of ≥8‑week statin trial at maximally tolerated dose
    • Document ezetimibe trial (8–12 weeks) or justification for not using ezetimibe
    Denial Risk

    Onychomycosis — denial triggers for missing diagnostics or prior therapy

    Onychomycosis PA requests missing confirmatory diagnostic testing (KOH/culture/histology), lack of documentation of ADL impact, or missing prior failure/intolerance to required systemic/topical therapies may be denied.

    • Attach KOH, culture, or histology confirming dermatophyte infection
    • Document functional impact and prior therapy failures/intolerance
    Denial Risk

    PAH — denial risk if diagnostic hemodynamics or WHO Group I not documented

    PAH agent requests without documented WHO Group I PAH diagnosis with NYHA II–IV, confirmatory catheterization/echocardiography, and mean pulmonary artery pressure ≥25 mm Hg at rest (or >30 with exertion) may be denied.

    • Provide right‑heart catheterization or echocardiography and mPAP data
    • Include NYHA functional class and specialist consultation
    Denial Risk

    PCSK9/Praluent — LDL and statin trial documentation required to avoid denial

    For PCSK9 inhibitors (e.g., Praluent), missing documentation of LDL‑C thresholds after an adequate statin trial or lack of documented statin intolerance per specified criteria may lead to denial.

    • Include LDL‑C values and evidence of ≥8‑week moderate‑intensity statin trial
    • If statin‑intolerant, document clinical criteria (rhabdomyolysis, CK elevations, hepatotoxicity) as specified
    Denial Risk

    Concurrent biologic/JAK therapy excluded — denial risk

    Concurrent therapy with other biologic DMARDs or JAK inhibitors is an exclusion for multiple indications and may trigger denial if such concomitant use is documented.

    • Verify patient's current biologic/JAK therapy prior to PA submission
    • If concurrent therapy is present, the request will generally be denied
    Denial Risk

    Concomitant nitrate use exclusion — sildenafil/PAH

    Documentation of concomitant nitrate use is an exclusion for sildenafil (PAH) and can trigger denial; confirm medication list for nitrates before submission.

    • Check for concurrent nitrates or nitric oxide donors
    • Provide documentation that nitrates are not being used
    Denial Risk

    Concurrent biologic therapy excluded for PsO/PsA/UC/CD

    Concurrent therapy with biological DMARDs or TNF antagonists for indications such as psoriasis, psoriatic arthritis, UC, and CD is an exclusion and will result in denial unless the policy permits otherwise.

    • Do not request overlapping biologic therapies for listed indications
    • Provide evidence patient is not on another biologic for the same disease
    Denial Risk

    PAH — combination with prostanoid/prostacyclin excluded

    Use of PAH agents in combination with a prostanoid/prostacyclin analogue is an exclusion and may result in denial; verify current prostanoid therapy before requesting PAH medications covered here.

    • Confirm patient is not receiving prostanoid/prostacyclin analogues
    • If combined use is clinically required, include justification and check policy exceptions
    Denial Risk

    Asthma/allergy biologics — concurrent biologic therapy excluded

    Concurrent therapy with any other biologic agents for asthma/allergic conditions (e.g., benralizumab, dupilumab, mepolizumab, omalizumab) is excluded and may trigger denial for those products.

    • Ensure no concurrent biologic for asthma/allergic conditions is being used
    • Provide documentation of lack of overlapping biologic therapy
    Note

    Coding and Clinical Thresholds

    Codes referencedmixed
    none listedNo explicit CPT/HCPCS/ICD codes present in this segment
    Product name listing (no specific billing codes provided in this segment)mixed
    No codes listed
    Product presentations / dosages listedNDC|package
    560 mcg/2.24mldosage/packaging listed
    Testosterone formulationsmixed
    testosterone cypionate 100 mg/mlintramuscular solution
    testosterone cypionate 200 mg/mlintramuscular solution
    testosterone enanthate intramuscular solutionproduct listed
    transdermal gels/solutions (multiple strengths)various transdermal testosterone formulations listed
    Selected product codes/namesNDC|brand
    XIFAXAN 550 mgrifaximin oral tablet 550 mg
    VOWSTfecal microbiota, live-jslm (Vowst) product
    Index entries (no billing codes listed)mixed
    No codes listed
    inv-116: FEV1 (25% - 75% of predicted)
    FEV1 range25% - 75% of predicted
    Indication contextUsed as entry criterion for inhaled aztreonam (Cayston) in cystic fibrosis patients with documented Pseudomonas aeruginosa
    Age restriction noteApplies to members age 7 years and older for Cayston
    inv-117: LIC (liver iron concentration) >=5 mg Fe/g dw
    LIC threshold>= 5 mg Fe/g dw
    ContextRequired for Deferasirox NTDT initial approval (non–transfusion-dependent thalassemia)
    Age limitationNTDT initial: member must be >= 10 years
    inv-118: Serum ferritin (NTDT) > 300 mcg/L (two values)
    Serum ferritin (NTDT) threshold> 300 mcg/L (consistent with at least two lab values within the previous two months)
    Documentation requirementAt least two ferritin values within prior two months to demonstrate consistency
    Associated criterionUsed with LIC >=5 mg Fe/g dw for Deferasirox NTDT initial approval
    inv-119: Serum ferritin (CIO-BT) > 1000 mcg/L (two values)
    Serum ferritin (CIO-BT) threshold> 1000 mcg/L (consistent with at least two lab values within the previous two months)
    IndicationRequired for Deferasirox for chronic iron overload caused by blood transfusions (CIO-BT)
    Age limitationCIO-BT initial: member must be >= 2 years
    inv-120: Platelet count (CLD procedure) < 50,000/mcL
    Platelet threshold (CLD procedure)< 50,000/mcL
    ContextIndication for avatrombopag (Doptelet) to raise platelets prior to procedure in chronic liver disease
    Coverage duration noteCLD indication coverage duration: 1 month
    inv-121: Platelet count (ITP) < 30,000/mcL
    Platelet threshold (ITP)< 30,000/mcL
    ContextBaseline platelet count requirement for chronic immune thrombocytopenia prior to eltrombopag/avatrombopag initiation
    Continuation requirementContinuation requires positive clinical response (increase in platelet count to avoid bleeding)
    inv-122: Eosinophils for asthma >=150 cells/mcL baseline or >=300 cells/mcL in past 12 months
    Asthma eosinophil thresholds>=150 cells/mcL at baseline or >=300 cells/mcL within past 12 months
    Use caseDefines eosinophilic phenotype for severe asthma eligibility for certain biologics (e.g., Dupixent, Fasenra)
    Measurement timingBaseline value or documented value within prior 12 months accepted
    inv-123: Eosinophils for EoE >=15 intraepithelial eosinophils per HPF
    EoE histology threshold>=15 intraepithelial eosinophils per HPF
    ContextRequired biopsy finding for eosinophilic esophagitis initial approval (e.g., Dupixent EoE criteria)
    Additional requirementsSymptoms of esophageal dysfunction and exclusion of other causes also required
    inv-124: Blood eosinophil thresholds >=150 or >=300 cells/mcL
    Blood eosinophil thresholds>=150 cells/mcL (if oral corticosteroid-dependent) or >=300 cells/mcL
    PurposeDefines severe asthma with eosinophilic phenotype for biologic coverage (e.g., Fasenra, Nucala)
    Clinical linkThresholds combined with exacerbation history and high-dose ICS/controller use
    inv-125: EoE histology >=15 eos/HPF
    EoE histology requirement>=15 intraepithelial eosinophils per HPF on esophageal biopsy
    Associated clinical criteriaPlus symptoms of esophageal dysfunction, weight >=15 kg, and failed 8-week PPI or topical steroid trial
    Exclusion noteOther causes of esophageal eosinophilia must be excluded
    inv-126: Opioid tolerance definitions for high-dose therapy
    Opioid tolerance exampleAt least one week where total daily dose >=30 mg oxycodone or 60 mg oral morphine or 8 mg oral hydromorphone
    New-to-high-dose prerequisiteRequired for initiation of new high-dose opioid therapy for chronic non-cancer pain unless cancer-related
    Continuing therapy metricContinuing high-dose therapy defined as morphine equivalent >=90 mg/day with pain reassessed within 6 months
    inv-127: LDL-C thresholds for Nexletol/Nexlizet and related rules
    Nexletol/Nexlizet LDL-C thresholdsLDL-C >=70 mg/dL after a minimum 8-week trial of at least moderate-intensity statin therapy (additional higher thresholds apply per specific indication)
    Prior therapy requirementMinimum 8-week statin trial and at least 8–12 weeks of ezetimibe as applicable before Nexletol/Nexlizet
    Coverage timingInitial coverage commonly 6 months; continuation 12 months contingent on response
    inv-128: Eosinophil count for Nucala (HES) >=1000 cells/µL pretreatment
    Nucala (HES) eosinophil threshold>=1000 cells/µL pretreatment
    ContextRequired for HES indication initial approval for mepolizumab (Nucala)
    Age restrictionHES indication: member must be >=12 years
    inv-129: Eosinophil thresholds for Nucala (Severe Asthma/COPD)
    Nucala severe asthma/COPD eosinophil thresholds>=150 cells/µL at initiation or >=300 cells/µL in last 12 months
    Use caseApplies to severe eosinophilic asthma and COPD type 2 inflammation eligibility for mepolizumab
    Additional clinical criteriaExacerbation history and background high-dose ICS/controller therapy required for asthma pathway
    inv-130: Diabetes diagnostic labs (A1C/FPG/OGTT thresholds)
    Diabetes diagnostic A1C thresholdA1C >=6.5%
    Fasting plasma glucose thresholdFPG >=126 mg/dL
    2-hour OGTT threshold2-hour OGTT >=200 mg/dL
    inv-131: Mean pulmonary artery pressure >=25 mm Hg at rest
    Mean pulmonary artery pressure threshold>= 25 mm Hg at rest (or >30 mm Hg with exertion)
    Diagnostic contextRequired for diagnosis confirmation of Pulmonary Arterial Hypertension (WHO Group I) for PAH therapies
    Confirmation methodsDocumented by right-heart catheterization or echocardiography per policy
    inv-132: LDL-C thresholds for Praluent
    Praluent LDL-C threshold (HLA/ASCVD)LDL-C >=70 mg/dL after minimum 8-week moderate-intensity statin trial; HoFH: untreated LDL-C >500 mg/dL or treated LDL-C >300 mg/dL
    Prior therapy requirementMinimum 8-week statin trial or documentation of statin intolerance per specified criteria
    Coverage durationsInitial 6 months; continuation 12 months with documented response
    inv-133: Platelet count threshold for ITP (<30,000/mcL)
    ITP platelet threshold< 30,000/mcL baseline
    ContextBaseline requirement for chronic ITP prior to eltrombopag/Doptelet initiation
    Continuation requirementContinuation requires positive clinical response (increase in platelet count)
    inv-134: Diabetes diagnostic thresholds (duplicate reference)
    A1C diagnostic thresholdA1C >= 6.5%
    FPG diagnostic thresholdFPG >=126 mg/dL
    OGTT diagnostic threshold2-hr OGTT >=200 mg/dL
    inv-135: LDL-C threshold >=70 mg/dL
    LDL-C threshold (general)>= 70 mg/dL
    Use caseUsed as a benchmark for PCSK9 and other lipid-lowering therapy PA policies after statin trial
    Documentation timingLDL-C should be from within the prior 120 days where specified
    inv-136: BMD T-score <= -2.5
    BMD T-score criterion<= -2.5
    ContextDiagnostic threshold for osteoporosis and eligibility for certain anabolic/teriparatide therapies
    Alternate high-risk definitionsHistory of multiple vertebral fractures or history of osteoporotic low-trauma fracture also qualifies
    inv-137: Mean pulmonary artery pressure (duplicate entry)
    Mean PAP rest threshold>= 25 mm Hg at rest (or >30 mm Hg with exertion)
    Diagnostic confirmationRequires catheterization or echocardiography and specialist involvement (cardiology/pulmonology)
    Coverage timingInitial PAH approvals commonly 6 months; continuation 12 months with documented stabilization/improvement
    inv-138: Prednisone exposure for GCO >=5 mg daily for >=3 months
    Prednisone exposure for GCO>= 5 mg daily for >= 3 months
    ContextRequired for glucocorticoid-induced osteoporosis initial eligibility
    Related requirementPlus inadequate response or intolerance to bisphosphonates/hormone therapy/SERMs or denosumab when specified
    inv-139: Glucocorticoid dose threshold (prednisone >=5 mg daily >=3 months)
    Glucocorticoid dose thresholdprednisone ≥ 5 mg daily for at least 3 months
    PurposeDefines exposure threshold for Glucocorticoid-Induced Osteoporosis (GCO) coverage consideration
    Age/coverage noteApplies to adults (HGO, PMO, GCO policies specify age >=18 years for initial/reauth),
    inv-140: Hypogonadism lab threshold (two early morning total testosterone <300 ng/dL)
    Hypogonadism lab confirmationTwo early morning total testosterone <300 ng/dL on separate occasions
    Additional labsNormal prolactin required and compatible symptoms of testosterone deficiency
    Age considerationsMember age limits apply: some testosterone formulations limited to >=18 years; generic testosterone cypionate may be used >=12 years per policy
    inv-141: Mean pulmonary artery pressure (third duplicate)
    Mean pulmonary artery pressure≥ 25 mm Hg at rest (or >30 mm Hg with exertion)
    Diagnostic requirementPart of PAH WHO Group I criteria requiring catheterization/echocardiography
    Specialist involvementPrescribed by or in consultation with cardiologist or pulmonologist
    inv-142: Baseline serum total IgE ranges for allergic indications
    Baseline total IgE ranges30–1300 IU/mL for allergic asthma; 30–1850 IU/mL for IgE‑mediated food allergy
    ApplicationRequired baseline IgE for omalizumab (Xolair) eligibility and dosing for IMFA (dosing based on IgE and weight)
    Age limitsAllergic asthma: member >=6 years; IMFA: member >=1 year; nasal polyps: member >=18 years

    Quantity Limits and Course Limits

    inv-272: Promacta (eltrombopag) quantity limits
    Promacta QL noteQuantity limits applied per indication; continuation requires evidence of clinical response
    Indications affectedITP, FLSAA, RSAA, HEPC-TP with different initial/continuation durations
    Part B/Part DPromacta is reviewed under Part D for listed indications; no specific numeric QL provided in this segment
    inv-273: XIFAXAN quantity limit — ≤ 3 total courses (42 days total)
    Xifaxan course limit≤ 3 total courses (42 days total)
    Indications and per-course durationApplicable to IBS-D and certain SBBO/SIBO indications; each course duration typically 2 weeks
    Step therapy contextRequires prior inadequate response/intolerance to listed agents (e.g., one TCA or SSRI and dicyclomine) for IBS-D
    inv-274: VOWST quantity limit — 1 course
    Vowst quantity limit1 course
    Course durationCoverage duration: 14 days per approved course
    PrerequisitesDocumented recurrent CDI (>=2 recurrences in 12 months) and completion of recommended antibiotic and bowel prep prior to instillation

    Site of Care and Billing Considerations

    Billing Rule

    Site-of‑care — Part B vs Part D review for infusion/clinic/home

    Site-of-care determinations may affect benefit coverage (Part B vs Part D). For products administered in infusion center, office, or home settings, Part B vs Part D review and billing determinations should be considered when submitting requests.

    • Confirm site of care and whether Part B or Part D applies for the product and patient
    • Include documentation of administration setting when relevant
    Documentation Required

    PAH prescribing specialty — cardiology/pulmonology requirement

    Pulmonary arterial hypertension agents should be prescribed by or in consultation with a cardiologist or pulmonologist; include specialist involvement in the PA submission.

    • Document cardiology or pulmonology prescriber or consultation
    • Specialist evaluation supports PA approval and continuation assessments
    Documentation Required

    Orkambi — prescribing specialty requirement

    Orkambi should be prescribed by or in consultation with a pulmonologist or cystic fibrosis specialist; include this specialty documentation with the prior authorization request.

    • Provide pulmonologist or CF specialist prescriber/consultation note
    • Attach relevant CF diagnostic and mutation testing information if requested
    Documentation Required

    Specialty prescriber and site-of-care — include specialist and setting

    Many specialty products require specialist prescribing or consultation (infusion center, clinic, or provider‑specified specialty). For certain agents, specify the infusion/clinic/specialty site and include the prescribing specialist in the PA documentation.

    • For transplant, infectious disease, or GI specialty agents include relevant specialist consultation
    • Document site-of-care if product is administered in infusion center, clinic, or specialty setting
    Billing Rule

    Infusion center — Part B vs Part D billing/site‑of‑care note

    When the product is administered in an infusion center, Part B vs Part D review may apply; include site-of-care and billing preference information to support correct benefit routing.

    • Indicate infusion center administration and whether Part B billing is expected
    • Attach documentation supporting site-of-care billing determination where specified

    Definitions and Diagnostic Thresholds

    inv-215: Utilization management — definitions (PA, ST, QL)
    PA definitionPrior Authorization (PA): plan requires approval from the plan before filling certain prescriptions
    ST definitionStep Therapy (ST): requires trying specified drugs before covering another drug
    QL definitionQuantity Limits (QL): limits on the amount of drug the plan will cover
    inv-216: Severe asthma with eosinophilic phenotype definition
    Severe eosinophilic asthma definitionBlood eosinophils >=150 cells/µL if oral corticosteroid-dependent or >=300 cells/µL otherwise, plus exacerbation history and high‑dose ICS plus another controller
    Clinical componentsRequires >=1 exacerbation needing systemic steroids in past 12 months or prior intubation/hospitalization
    Prescriber requirementPrescribed by or in consultation with pulmonologist or allergy/immunology specialist
    inv-217: EoE histologic threshold
    EoE histologic threshold>=15 intraepithelial eosinophils per high power field (HPF)
    Associated clinical requirementSymptoms of esophageal dysfunction and exclusion of other causes required
    Age noteEoE initial/reauth applies to members >=1 year
    inv-218: OSAHS definition
    OSAHS definitionObstructive Sleep Apnea/Hypopnea Syndrome: sleep study with >=5 obstructive respiratory events/hour plus associated symptoms
    Study requirementSleep study confirmation required unless prescriber documents infeasibility
    PrescriberPrescribed by or in consultation with neurologist or sleep specialist
    inv-219: IPF definition
    IPF confirmationIdiopathic Pulmonary Fibrosis confirmed by high-resolution CT scan or biopsy
    SpecialistPrescribed by or in consultation with pulmonologist or lung transplant specialist
    Reauth criteriaReauthorization requires stabilization from baseline and liver enzyme safety checks
    inv-220: PAH WHO Group I definition
    PAH WHO Group I definitionPAH WHO Group I with NYHA Functional Class II–IV confirmed by right‑heart catheterization or echocardiography
    Hemodynamic criterionMean pulmonary artery pressure >=25 mm Hg at rest (or >30 mm Hg with exertion)
    Prescriber requirementPrescribed by or in consultation with cardiologist or pulmonologist
    inv-221: PAH diagnostic criteria (restatement)
    PAH diagnostic criteria summaryDiagnosis confirmed by catheterization or echocardiography plus mean PAP >=25 mm Hg at rest (>=30 mm Hg with exertion) and NYHA II–IV
    Initial/continuation durationsInitial approvals commonly 6 months; continuation 12 months contingent on stabilization/improvement
    Denial riskAbsence of documented WHO Group I diagnosis, NYHA II–IV, or confirmatory hemodynamics may trigger denial
    inv-222: ATTR-CM diagnostic approaches
    ATTR-CM diagnostic approachesDiagnosis confirmed by TTR mutation, tissue biopsy showing TTR amyloid, or combined imaging (echo/MRI and scintigraphy) with exclusion of light‑chain amyloidosis
    Clinical requirementsPlus history of heart failure or HF hospitalization and NYHA I–III for tafamidis coverage
    SpecialistPrescribed by or in consultation with a cardiologist
    inv-223: High to very high risk for fracture definition
    High-to-very-high fracture risk definitionOne of: multiple vertebral fractures, BMD T-score <= -2.5, or history of osteoporotic low‑trauma fracture (hip, spine, pelvis, distal forearm)
    Use caseDefines eligibility for anabolic osteoporosis agents (e.g., teriparatide) and high‑risk management
    Age requirementPolicies for HGO/PMO/GCO apply to members >=18 years
    inv-224: Recurrent C. difficile infection (Vowst) definition
    Recurrent C. difficile infection definition>=3 loose stools/day for >=2 consecutive days plus positive stool test and history of >=2 recurrent CDI episodes within 12 months
    Vowst prerequisitesCompletion of recommended antibiotic course 2–4 days prior and bowel prep before instillation
    Age restrictionMember must be >=18 years for Vowst PCDI coverage
    inv-225: Reauthorization clinical response definition
    Reauthorization clinical responseEvidence of positive clinical response since last authorization (e.g., reduced exacerbations, improved FEV1, decreased rescue use)
    DocumentationReauth generally requires objective measures of benefit and specialist evaluation where applicable
    Typical reauth intervalReauthorizations commonly granted for 12 months when response demonstrated

    Background and Scope

    This formulary supplement describes utilization management tools (Prior Authorization, Step Therapy, Quantity Limits) and the clinical criteria used to align specialty drug dispensing with evidence-based practice and safety considerations. It lists indication-specific requirements such as diagnostic confirmation, required prior medication trials, prescriber specialty and age restrictions, safety exclusions (for example concurrent biologic use or cardiac contraindications), and documentation expectations that providers must supply to support coverage decisions.